THRD's Business Model
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.thirdharmonicbio.com |
| CEO (Chief Executive Officer) | Natalie C. Holles |
| Number of Employees | |
| IPO date | September 14, 2022 |
THRD Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 300 Technology Square |
| City | Cambridge |
| State | MA |
| Phone | 617-915-6680 |
| Zip Code | 02139 |
| Other Identifiers | |
| CIK | 0001923840 |
| ISIN | US88427A1079 |
| CUSIP | 88427A107 |
| Open | 5.38 |
| Previous Close | 5.385 |
| Volume | 1.42 Mil. |
| Average Volume | 262.8 Thou. |
| Day’s Range | 5.38 – 5.38 |
| 52 Week Range | 3.18-16.02 |
| MA (50) | 5.375 |
| MA (200) | 7.0131 |
| Market Cap | 242.8 Mil. |
| Shares Out. | 45.13 Mil. |
| Earnings Date | Aug 06, 2025 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
